swish30

swish30

Advisory committee has voted in favour of Hepatitis-B vaccine. Now just waiting for FDA approval expected no later than November 10.

swish30

Waiting for Phase 2 data to restart the hype for this low floater.

swish30

Waiting on an update on Phase 2 trials in melanoma patients expected in Q4. Stock could rally from Fibonacci setup after the conference. Buy zone: 2.70 Profit zone: 3.00 or higher Stop zone: 2.55 or lower

swish30

Phase 2 trial results due anytime now. Watching for levels where CEO and CMO have been buying to potentially get in.

swish30

Waiting for a spike to trade if good trial data comes out.

swish30

Could see high volatility given that this is there main product.

swish30

Insiders bought recently before the offering at $1.10 per share. Slightly risky when Actimab-A Phase 2 results could come out anytime.

swish30

Looking for a potential run-up heading into the PDUFA announcement on 30-Dec. Reasoning: Ex-CEO David Dodd left the company just before a lawsuit was launched against him for trying to obtain personal rights for the lead drug candidate Macrilen. For him to act in such a way, its quite possible that he see good future potential for the product. Buy zone: $1.60 -...

swish30

Immuno-oncology stock that has recently completed an offering of common stock @ $0.75 per share. Stock looks to have bottomed out. Buy a for a potential 10-20% bounce.